JPWO2020081839A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020081839A5
JPWO2020081839A5 JP2021515005A JP2021515005A JPWO2020081839A5 JP WO2020081839 A5 JPWO2020081839 A5 JP WO2020081839A5 JP 2021515005 A JP2021515005 A JP 2021515005A JP 2021515005 A JP2021515005 A JP 2021515005A JP WO2020081839 A5 JPWO2020081839 A5 JP WO2020081839A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pharmaceutically acceptable
administered
patient
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021515005A
Other languages
Japanese (ja)
Other versions
JP2022503733A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/056772 external-priority patent/WO2020081839A1/en
Publication of JP2022503733A publication Critical patent/JP2022503733A/en
Publication of JPWO2020081839A5 publication Critical patent/JPWO2020081839A5/ja
Pending legal-status Critical Current

Links

Claims (21)

口腔粘膜炎の治療を必要とする患者において口腔粘膜炎を治療するために投与される医薬組成物であって、有効量の下記式を有する化合物
Figure 2020081839000001
またはその薬学的に許容される塩を含む上記医薬組成物。 A pharmaceutical composition administered to treat oral mucositis in a patient in need thereof, comprising an effective amount of a compound having the formula:
Figure 2020081839000001
or the above pharmaceutical composition containing a pharmaceutically acceptable salt thereof . 前記投与が局所投与である、請求項１に記載の医薬組成物。 2. The pharmaceutical composition of claim 1, wherein said administration is topical administration. 前記局所投与が前記患者の口腔に適用される、請求項２に記載の医薬組成物。 3. The pharmaceutical composition of claim 2, wherein said topical administration is applied to said patient's oral cavity. 前記医薬組成物が、ゲル、軟膏、油、溶液、懸濁液、乳濁液または他の粘性組成物である、請求項１に記載の医薬組成物。 2. The pharmaceutical composition according to claim 1, wherein said pharmaceutical composition is a gel, ointment, oil, solution, suspension, emulsion or other viscous composition . 前記医薬組成物が含嗽液である、請求項１に記載の医薬組成物。 2. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition is a mouthwash. 少なくとも１つのさらなる活性成分をさらに含む、請求項１に記載の医薬組成物。 2. The pharmaceutical composition according to claim 1, further comprising at least one additional active ingredient. 薬学的に許容される担体をさらに含む、請求項１に記載の医薬組成物。 2. The pharmaceutical composition of Claim 1, further comprising a pharmaceutically acceptable carrier. 前記医薬組成物が複数回投与レジメンとして投与されるように製剤化されている、請求項１に記載の医薬組成物。 2. The pharmaceutical composition of claim 1, wherein said pharmaceutical composition is formulated to be administered as a multiple dose regimen. 前記医薬組成物が１日１回以上投与されるように製剤化されている、請求項８に記載の医薬組成物。 9. The pharmaceutical composition of Claim 8, wherein said pharmaceutical composition is formulated to be administered one or more times per day. 前記患者がヒトである、請求項１に記載の医薬組成物。 2. The pharmaceutical composition of claim 1, wherein said patient is human. 口腔粘膜炎の治療を必要とする患者において口腔粘膜炎を治療するために投与される医薬組成物であって、有効量の下記式を有する化合物
Figure 2020081839000002
またはその薬学的に許容される塩、および薬学的に許容される担体を含み、前記医薬組成物が前記患者の口腔に局所投与されるように製剤化されている、上記医薬組成物。 A pharmaceutical composition administered to treat oral mucositis in a patient in need thereof, comprising an effective amount of a compound having the formula:
Figure 2020081839000002
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier , wherein the pharmaceutical composition is formulated for topical administration to the patient's oral cavity . 前記医薬組成物が、ゲル、軟膏、油、溶液、懸濁液、乳濁液または他の粘性組成物である、請求項１１に記載の医薬組成物。 12. The pharmaceutical composition according to claim 11, wherein said pharmaceutical composition is a gel, ointment, oil, solution, suspension, emulsion or other viscous composition . 前記医薬組成物が含嗽液である、請求項１１に記載の医薬組成物。 12. The pharmaceutical composition according to claim 11, wherein said pharmaceutical composition is a mouthwash. 前記化合物またはその薬学的に許容される塩が約１％～約２０％（重量／重量）の量で前記医薬組成物中に存在する、請求項１１に記載の医薬組成物。 12. The pharmaceutical composition of claim 11, wherein said compound or pharmaceutically acceptable salt thereof is present in said pharmaceutical composition in an amount of about 1% to about 20% (w/w). 前記化合物またはその薬学的に許容される塩が約５％～約１５％（重量／重量）の量で前記医薬組成物中に存在する、請求項１４に記載の医薬組成物。 15. The pharmaceutical composition of claim 14, wherein said compound or pharmaceutically acceptable salt thereof is present in said pharmaceutical composition in an amount of about 5% to about 15% (w/w). 前記化合物またはその薬学的に許容される塩が約３０％～約５０％（重量／重量）の量で前記医薬組成物中に存在する、請求項１１に記載の医薬組成物。 12. The pharmaceutical composition of claim 11, wherein said compound or pharmaceutically acceptable salt thereof is present in said pharmaceutical composition in an amount of about 30% to about 50% (w/w). 前記医薬組成物が複数回投与レジメンとして投与されるように製剤化されている、請求項１１に記載の医薬組成物。 12. The pharmaceutical composition of claim 11, wherein said pharmaceutical composition is formulated to be administered as a multiple dose regimen. 前記医薬組成物が１日１回以上投与されるように製剤化されている、請求項１１に記載の医薬組成物。 12. The pharmaceutical composition of claim 11, wherein said pharmaceutical composition is formulated to be administered one or more times per day. 前記患者がヒトである、請求項１１に記載の医薬組成物。 12. The pharmaceutical composition of claim 11, wherein said patient is human. 前記医薬組成物が約ｐＨ１．５～約ｐＨ４のｐＨを有する、請求項１１に記載の医薬組成物。 12. The pharmaceutical composition of claim 11 , wherein said pharmaceutical composition has a pH of about pH 1.5 to about pH 4. 前記医薬組成物が約ｐＨ３～約ｐＨ４のｐＨを有する、請求項１１に記載の医薬組成物。 12. The pharmaceutical composition of claim 11 , wherein said pharmaceutical composition has a pH of about pH3 to about pH4.
JP2021515005A 2018-10-17 2019-10-17 Methods and Compositions for Treating Oral Mucositis Pending JP2022503733A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746943P 2018-10-17 2018-10-17
US62/746,943 2018-10-17
PCT/US2019/056772 WO2020081839A1 (en) 2018-10-17 2019-10-17 Methods and compositions for treating oral mucositis

Publications (2)

Publication Number Publication Date
JP2022503733A JP2022503733A (en) 2022-01-12
JPWO2020081839A5 true JPWO2020081839A5 (en) 2022-10-26

Family

ID=70281364

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021515005A Pending JP2022503733A (en) 2018-10-17 2019-10-17 Methods and Compositions for Treating Oral Mucositis

Country Status (12)

Country Link
US (2) US11123357B2 (en)
EP (1) EP3866810A4 (en)
JP (1) JP2022503733A (en)
KR (1) KR20210075968A (en)
CN (1) CN112839662A (en)
AU (1) AU2019361999A1 (en)
BR (1) BR112021006954A2 (en)
CA (1) CA3116157A1 (en)
IL (1) IL282100A (en)
MX (1) MX2021004396A (en)
SG (1) SG11202103180QA (en)
WO (1) WO2020081839A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11795192B2 (en) * 2017-03-10 2023-10-24 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4421769A (en) 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
US5167950A (en) 1991-03-28 1992-12-01 S. C. Johnson & Son High alcohol content aerosol antimicrobial mousse
CN1145582A (en) 1994-03-11 1997-03-19 普罗克特和甘保尔公司 Low pH, hydrolytically stable, cosmetic compsn. containing acidic actives
US20020032164A1 (en) 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
US6211349B1 (en) 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US7868162B2 (en) 1998-12-30 2011-01-11 Lakewood-Amedex, Inc. Antimicrobial and antiviral compounds and methods for their use
US6211162B1 (en) 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
NZ513402A (en) 1999-02-12 2003-06-30 Sankyo Co Novel nucleosides and oligonucleotide analogues
US6946118B1 (en) * 1999-09-14 2005-09-20 Orapharma, Inc. Formulations for treating or preventing mucositis
US6156294A (en) 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
JP2005511526A (en) 2001-10-18 2005-04-28 イレックス プロダクツ インコーポレイテッド Skin treatment with diphosphonate derivatives
EP1509234B1 (en) * 2002-05-21 2008-12-17 Abbott Laboratories Treatment of mucositis
CN1687100A (en) * 2005-04-05 2005-10-26 奥林格斯技术有限公司 Modification nucleotide and its use
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
US8884000B2 (en) 2010-02-17 2014-11-11 Albert Einstein College Of Medicine Of Yeshiva University Saporin-L1 inhibitors and uses thereof
EP2601205A2 (en) * 2010-08-03 2013-06-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Guanine nucleotide derivatives for treating bacterial infections
US9765020B2 (en) * 2012-05-23 2017-09-19 Cellix Bio Private Limited Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis
WO2014124430A1 (en) 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
CA2966213A1 (en) * 2014-10-30 2016-05-06 Biomet Manufacturing, Llc Methods of preventing surgical site infections
US10172786B2 (en) * 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
WO2017165673A1 (en) * 2016-03-23 2017-09-28 University Of Utah Research Foundation Spinal traction device
BR112019018615B1 (en) * 2017-03-10 2021-11-16 Lakewood Amedex, Inc. ANTIMICROBIAL COMPOUND AND ITS PHARMACEUTICAL COMPOSITION
EP3638251B1 (en) * 2017-06-12 2024-03-06 Lakewood Amedex, Inc. Bisphosphocin gel formulations and uses thereof

Similar Documents

Publication Publication Date Title
JP2668800B2 (en) Topical treatment for skin diseases
US5648399A (en) Liquid polymer composition and method of use
JP2019189650A5 (en)
JP3597333B2 (en) Pharmaceutical preparations for treating acute rhinitis
JPH032126A (en) Oral antifungal preventive and use thereof
JPS6061524A (en) Treatment for tooth socket bone absorption
IE910317A1 (en) Topical preparations for treating human nails
JPH0597668A (en) Treatment of gum inflammation
CA2519980A1 (en) Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
JP2590156B2 (en) Pharmaceutical composition for oral administration
RU2005133665A (en) APPLICATION OF 10-HYDROXY-10,11-DIHYDROCARBAMAZEPINE DERIVATIVES FOR THE TREATMENT OF AFFECTIVE DISORDERS
JPH0489428A (en) Polymorphonuclear leukocyte activator
ES2246888T3 (en) TREATMENT OF INFECTIONS BY FUNGI USING A MEANS OF FUNGICAL GROWTH.
RU2005105302A (en) BICYPHADINE COMPOSITION
JPWO2020081839A5 (en)
US20110160166A1 (en) Therapeutic composition for the treatment and prevention of athlete's foot and fungal infections of the nail and surrounding tissues
GB2167296A (en) Topical pharmaceutical compositions containing glycyrrhizin
JP2008519848A5 (en)
US20080268022A1 (en) Mehtods for treating and preventing ailments caused by human papillomavirus
US7655668B1 (en) Composition and method for treatment of warts
AU754329B2 (en) Fungicide composition comprising a benzoylphenylurea
EP0086228A1 (en) Use of carbamide peroxide for the manufacture of a medicament for treatment of acne vulgaris.
US2988480A (en) Therapeutically active compositions
RU2467738C1 (en) Dental ointment with chlorhexidine and aminocapronic acid for integrated treatment of inflammatory periodontal diseases
US11951082B2 (en) Composition of chlorhexidine